April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular weight-loss med at $499 per month. Novo had only launched the cheaper ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...